Kannalife Sciences was mentioned in an article by The Daily Chronic that questions the drug policy in the NFL and how many players suffer from chronic pain after playing in the league.
“It was reported earlier this week that New York-based KannaLife Sciences signed a license agreement with the National Institutes of Health to allow the company to sell FDA-approved cannabis-derived medicines to treat chronic traumatic encephalopathy (CTE), a degenerative disease that affects people — particularly NFL athletes — who have endured repeated head trauma. However, KannaLife Sciences isn’t expected to begin clinical trials until 2015, with an approved drug still years away, and the NFL is currently being pressured to find effective treatments for CTE.”
